BIOTECH ASSISTANT / FIELD NOTES

Sarepta closes ENVISION enrollment and will analyze existing blinded trial data

Company / institutional announcement · Sarepta Therapeutics

Source published: 2026-11-05 · Event / reporting date: 2026-11-05

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Sarepta said it will not reopen enrollment in the Phase 3 ENVISION study of ELEVIDYS after a prolonged global clinical hold, and will analyze existing Part 1 blinded data. The company continues enrolling nonambulatory participants in ENDEAVOR Cohort 8 to study a preventive immunosuppressive regimen. ELEVIDYS is AAV gene delivery, distinct from in vivo gene editing or CAR-T engineering.

Why it may matter

Potential business implication: vector-delivery programs must align safety mitigation with interpretable trial designs; closing one trial does not end all related research.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

In Vivo Cell Engineering & Gene Editing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Immorna Strand Therapeutics Orna Therapeutics Orbital Therapeutics Aanastra

Explore field companies →Explore literature →

Related updates

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06CSPC Pharmaceutical Group

CSPC initiates first Chinese center for SYS6055-003 in vivo CAR-T trial

CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.

In Vivo Cell Engineering & Gene Editing China Clinical CROs & IIT Partners Ask AI ↗

2026-11-06Azalea Therapeutics / GlobeNewswire

Azalea reports durable tumor control with in vivo TRAC-CAR engineering in mice

Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗